Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 75.14
- Piotroski Score 2.00
- Grade Buy
- Symbol (APGE)
- Company Apogee Therapeutics, Inc.
- Price $58.02
- Changes Percentage (-0.03%)
- Change -$0.02
- Day Low $57.40
- Day High $59.06
- Year High $72.29
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $95.00
- High Stock Price Target $95.00
- Low Stock Price Target $95.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-83,985,000
Income Statement
Quarterly
Annual
Latest News of APGE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
Jane Henderson, CFO of Apogee Therapeutics Inc, sold 6,000 shares at $48.26 each on August 23, 2024. The company focuses on developing therapies for diseases with unmet medical needs. Henderson now ho...
By Yahoo! Finance | 1 month ago -
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics, Inc. is a biotechnology company focusing on developing biologics for conditions like atopic dermatitis, asthma, and COPD. Their primary products are extended half-life monoclonal ...
By Yahoo! Finance | 1 month ago -
Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Inc focuses on developing innovative treatments for medical conditions. An insider recently sold shares worth $298,464.45, adding to a trend of insider selling. Investors should co...
By Yahoo! Finance | 1 month ago
